BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shah C, Mramba LK, Bishnoi R, Bejjanki H, Chhatrala HS, Chandana SR. Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era. J Gastrointest Oncol 2017;8:789-98. [PMID: 29184682 DOI: 10.21037/jgo.2017.06.16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Domovitz T, Gal-Tanamy M. Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis. J Clin Med 2021;10:551. [PMID: 33540858 DOI: 10.3390/jcm10030551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Ho SY, Liu PH, Hsu CY, Ko CC, Huang YH, Su CW, Hsia CY, Lee RC, Hou MC, Huo TI. ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy. J Gastrointest Oncol 2021;12:722-34. [PMID: 34012661 DOI: 10.21037/jgo-20-332] [Reference Citation Analysis]
3 Jiang JM, Ohri N, Tang J, Moadel R, Cynamon J, Kaubisch A, Kinkhabwala M, Garg MK, Guha C, Kabarriti R. Centers with more therapeutic modalities are associated with improved outcomes for patients with hepatocellular carcinoma. J Gastrointest Oncol 2019;10:546-53. [PMID: 31183206 DOI: 10.21037/jgo.2019.01.30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Giannis D, Morsy S, Geropoulos G, Esagian SM, Sioutas GS, Moris D. The Epidemiology, Staging and Outcomes of Sarcomatoid Hepatocellular Carcinoma: A SEER Population Analysis. In Vivo 2021;35:393-9. [PMID: 33402488 DOI: 10.21873/invivo.12270] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Li B, Liu D, Yang P, Li HY, Wang D. miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway. Gene 2019;707:78-85. [PMID: 31075412 DOI: 10.1016/j.gene.2019.05.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
6 Liu C, Li J, Wang W, Zhong X, Xu F, Lu J. miR-206 inhibits liver cancer stem cell expansion by regulating EGFR expression. Cell Cycle 2020;19:1077-88. [PMID: 32286127 DOI: 10.1080/15384101.2020.1739808] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Adler Jaffe S, Myers O, Meisner ALW, Wiggins CL, Hill DA, McDougall JA. Relationship between Insurance Type at Diagnosis and Hepatocellular Carcinoma Survival. Cancer Epidemiol Biomarkers Prev 2020;29:300-7. [PMID: 31796525 DOI: 10.1158/1055-9965.EPI-19-0902] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zou H, Yang L. miR-378a-5p improved the prognosis and suppressed the progression of hepatocellular carcinoma by targeting the VEGF pathway. Transl Cancer Res 2020;9:1558-66. [PMID: 35117503 DOI: 10.21037/tcr.2020.01.46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Bangaru S, Marrero JA, Singal AG. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;51:78-89. [PMID: 31747082 DOI: 10.1111/apt.15573] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 15.7] [Reference Citation Analysis]
10 Kang D, Shim S, Cho J, Lim HK. Systematic Review of Studies Assessing the Health-Related Quality of Life of Hepatocellular Carcinoma Patients from 2009 to 2018. Korean J Radiol 2020;21:633-46. [PMID: 32410403 DOI: 10.3348/kjr.2019.0808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liu X, Lu Y, Qin S. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. Future Oncol 2021;17:2243-56. [PMID: 33663220 DOI: 10.2217/fon-2020-1290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Chan MV, Huo YR, Trieu N, Mitchelle A, George J, He E, Lee AU, Chang J, Yang J. Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool? Clin Gastroenterol Hepatol 2021:S1542-3565(21)00215-9. [PMID: 33662596 DOI: 10.1016/j.cgh.2021.02.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
13 Ryon EL, Kronenfeld JP, Lee RM, Yopp A, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Russell MC, Goel N, Merchant NB, Datta J. Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative Analysis. J Surg Oncol 2021;123:407-15. [PMID: 33125746 DOI: 10.1002/jso.26282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Ran R, Chen J, Cui L, Lin X, Fan M, Cong Z, Zhang H, Tan W, Zhang G, Zhang Y. miR-194 inhibits liver cancer stem cell expansion by regulating RAC1 pathway. Experimental Cell Research 2019;378:66-75. [DOI: 10.1016/j.yexcr.2019.03.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
15 Akada K, Koyama N, Miura Y, Aoshima K. Nationwide database analysis of insomnia, depression, and sleeping pill prescriptions in hepatocellular carcinoma patients. Curr Med Res Opin 2022;:1-28. [PMID: 35608320 DOI: 10.1080/03007995.2022.2081451] [Reference Citation Analysis]
16 Hasan B, Colak Y, Khalid RA, Castillo M, Castaneda D, Tandon K, Shaw JJ, Erim T, Zervos XB, Castro FJ, Al-Khalloufi K. Early Detection of Hepatocellular Carcinoma Recurrence in the Posttransplant Population: A Comparison of RETREAT and Cleveland Clinic Florida Scoring System. Transplant Proc 2021;53:193-9. [PMID: 33069486 DOI: 10.1016/j.transproceed.2020.09.015] [Reference Citation Analysis]
17 Zhang X, El-Serag HB, Thrift AP. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes Control 2021;32:317-25. [PMID: 33394207 DOI: 10.1007/s10552-020-01386-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wang MJ, Chen JJ, Song SH, Su J, Zhao LH, Liu QG, Yang T, Chen Z, Liu C, Fu ZR, Hu YP, Chen F. Inhibition of SIRT1 Limits Self-Renewal and Oncogenesis by Inducing Senescence of Liver Cancer Stem Cells. J Hepatocell Carcinoma 2021;8:685-99. [PMID: 34235106 DOI: 10.2147/JHC.S296234] [Reference Citation Analysis]
19 Franco RA, Fan Y, Jarosek S, Bae S, Galbraith J. Racial and Geographic Disparities in Hepatocellular Carcinoma Outcomes. Am J Prev Med 2018;55:S40-8. [PMID: 30670200 DOI: 10.1016/j.amepre.2018.05.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]